For example, in patients with hypertension or diabetes, serial RRI assessments could help identify individuals with subclinical microvascular damage who may benefit from earlier initiation or intensification of cardioprotective therapies (e.g., RAS blockers, SGLT2 inhibitors, GLP-1RAs). This evidence concerns the gene SLC5A2 and hypertensive disorder.